<DOC>
	<DOCNO>NCT00050089</DOCNO>
	<brief_summary>This 'pragmatic ' trial 2X2 open randomize study patient advance HIV disease fail conventional Highly Active Antiretroviral Therapy ( HAART ) regimens include three class anti-HIV drug . The first randomization allocate patient intend 3-month antiretroviral drug-free period ( ARDFP ) No ARDFP . The second randomization allocate patient Mega-ART ( 5+ drug ) Standard-ART ( 4 drug ) . The total study duration 6.5 year 5 year intake 1.5 year ( minimum ) follow-up ; median duration patient follow-up 4 year . The target sample size 390 patient provide 75 % power detect 30 % reduction hazard rate primary endpoint mega-ART . Sixty-four site participate trial -- 24 VA , 19 UK 21 Canada .</brief_summary>
	<brief_title>CSP # 512 - Options Management With Anti-Retrovirals</brief_title>
	<detailed_description>Primary Hypothesis : Compared patient Standard Antiretroviral Therapy ( ART ) , patient Mega-ART assume full compliance , experience 30 % reduction hazard reach clinical endpoint ( AIDS event death ) . Secondary Hypotheses : Time development new , non-HIV relate serious adverse event , health relate quality life , incidence grade 3 4 clinical laboratory adverse event change virological immunological marker ( CD4 cell count , viral load , resistance profile ) vary different treatment strategy . Interventions : Eligible patient randomize one four treatment strategy arm : 1 . No Antiretroviral Drug-Free Period ( No ARDFP ) Standard-ART 2 . No Antiretroviral Drug-Free Period ( No ARDFP ) Mega-ART 3 . Antiretroviral Drug-Free Period ( ARDFP ) Standard-ART 4 . Antiretroviral Drug-Free Period ( ARDFP ) Mega-ART Note : The 'first ' randomization ARDFP vs No ARDFP . Patients randomize No ARDFP receive 'second ' randomization time . However , patient randomize Antiretroviral Drug Free Period ( ARDFP ) receive 'second ' randomize assignment ( Standard Mega-ART ) end ARDFP . Note : All Serious Adverse Events cod use MedDRA cod dictionary ; ( serious ) Adverse Events collect part study cod use MedDRA standardize cod dictionary . This first trial Tri-National collaboration effort UK MRC , Canadian CIHR VA CSP . The OPTIMA Trial review approve CSEC October 12 , 2000 . The pre-kickoff meeting hold March 21 , 2001 Washington , DC . The VA study kickoff meet hold Dallas , TX May 16-18 , 2001 Canadian kickoff hold Toronto May 29 , 2001 . The UK individual site initiation . As October 17 , 2005 357 patient enrolled OPTIMA , 64 site three country ( 279 VA , 41 Canada 37 UK ) . To date 64 site actively participate study ( 24 VA , 19 UK 21 Canada ) . Last date patient follow-up December 31 , 2007 .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<criteria>Ability provide inform consent Age 18 year Serologic virologic diagnosis HIV infection Failure least two different multidrug regimen include drug 3 class patient tolerate laboratory evidence resistance drug 3 class Had least 3 month current ART still treatment Two recent result ( include screen ) current ART CD4 count less equal 300 cells/mm3 less equal 15 % , plasma viral load great equal 5,000 copies/ml ( Roche Amplicor , v1.0 ) , great equal 2,500 copies/ml ( bDNA : Bayer v3.0/Chiron v3.0 PCR : Roche Amplicor Monitor/COBAS v1.5 ) Pregnancy , breastfeed plan pregnancy Likelihood poor protocol followup MegaArt feasible ( due significant intolerance many ARV drug ) Serious , uncontrolled major opportunistic infection ( OI ) within 14 day screen Likelihood early death due nonHIV disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>AIDS</keyword>
	<keyword>antiretrovirals</keyword>
	<keyword>ART</keyword>
	<keyword>drug-free period</keyword>
	<keyword>HAART</keyword>
	<keyword>HIV</keyword>
	<keyword>human immunodeficiency virus</keyword>
	<keyword>randomize</keyword>
	<keyword>structure treatment interruption</keyword>
</DOC>